ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Ascendis’ TransCon PTH shows promise in phase 2 hypoparathyroidism trial
April 22, 2020Ascendis Pharma said that its prodrug candidate TransCon PTH has met key objectives in the phase 2 PaTH Forward trial in adult subjects with hypoparathyroidism. -
Shire granted EU conditional marketing authorisation for Natpar for the treatment of chronic hypopar
April 27, 2017Natpar is the first and only licensed recombinant human parathyroid hormone therapy for chronic hypoparathyroidism. -
CHMP recommends EU Conditional Marketing Authorisation for Natpar for patients with chronic hypopara
March 01, 2017If approved, Natpar would be the first licensed recombinant parathyroid hormone in Europe for the management of chronic hypoparathyroidism, the only endocrine-deficiency disorder with no hormone treatment.
Pharma Sources Insight January 2025
